New drugs and options in MBC: Are there drugs that must be offered to patients in 2023?

Joseph GLIGOROV
Oncologist, Paris, France
CONTINUE READING

Conjugated antibodies.

Joseph GLIGOROV
Oncologist, Paris, France
CONTINUE READING

Therapeutic options and systemic therapy.

Joseph GLIGOROV
Oncologist, Paris, France
CONTINUE READING

Thoughts on DESTINY-Breast04 for HER2-low metastatic breast cancer.

Joseph GLIGOROV
Oncologist, Paris, France
CONTINUE READING

Quelles stratégies thérapeutiques employer dans les pays émergents ?

Joseph GLIGOROV
Oncologue, Paris, France
CONTINUE READING

Comment dépasser les problématiques liées au choix de traitement dans les cancers du seins RH+ en phase précoce?

Joseph GLIGOROV 
Oncologue, Paris, France
CONTINUE READING

Copyright © 2026 - BCU